Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Gross Profit (2019 - 2024)

Benitec Biopharma's Gross Profit history spans 6 years, with the latest figure at -$3000.0 for Q1 2024.

  • For Q1 2024, Gross Profit fell 105.56% year-over-year to -$3000.0; the TTM value through Dec 2024 reached -$3000.0, up 93.48%, while the annual FY2024 figure was -$108000.0, 244.0% down from the prior year.
  • Gross Profit for Q1 2024 was -$3000.0 at Benitec Biopharma, down from -$1000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $127000.0 in Q1 2020 and bottomed at -$106000.0 in Q3 2023.
  • The 5-year median for Gross Profit is $7000.0 (2020), against an average of $6600.0.
  • The largest annual shift saw Gross Profit tumbled 1228.57% in 2020 before it soared 900.0% in 2022.
  • A 5-year view of Gross Profit shows it stood at -$18000.0 in 2020, then soared by 238.89% to $25000.0 in 2021, then tumbled by 44.0% to $14000.0 in 2022, then tumbled by 107.14% to -$1000.0 in 2023, then tumbled by 200.0% to -$3000.0 in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Gross Profit are -$3000.0 (Q1 2024), -$1000.0 (Q4 2023), and -$106000.0 (Q3 2023).